Teleflex (NYSE:TFX) Downgraded by Citizens Jmp to Market Perform

Teleflex (NYSE:TFX) was downgraded by stock analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research report issued on Thursday,Briefing.com Automated Import reports.

Several other equities analysts have also commented on TFX. Royal Bank of Canada decreased their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Truist Financial cut their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, Mizuho dropped their target price on Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and an average target price of $246.00.

Teleflex Trading Down 21.8 %

Teleflex stock traded down $38.64 during trading on Thursday, reaching $138.99. 3,336,240 shares of the company were exchanged, compared to its average volume of 612,579. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. Teleflex has a 52-week low of $135.95 and a 52-week high of $249.90. The stock’s 50 day simple moving average is $177.07 and its two-hundred day simple moving average is $206.17. The company has a market capitalization of $6.46 billion, a P/E ratio of 27.63, a PEG ratio of 1.73 and a beta of 1.16.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. On average, equities research analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TFX. Avior Wealth Management LLC lifted its position in Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock worth $38,000 after buying an additional 101 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Teleflex during the third quarter worth $40,000. Headlands Technologies LLC purchased a new position in Teleflex in the fourth quarter valued at about $29,000. True Wealth Design LLC increased its position in Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 166 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Teleflex during the 3rd quarter worth about $54,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.